Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma by Liang, Raimunde et al.
 
 
University of Birmingham
Targeted gene expression profile reveals CDK4 as
therapeutic target for selected patients with
adrenocortical carcinoma
Liang, Raimunde; Weigand, Isabel; Lippert, Juliane; Kircher, Stefan; Altieri, Barbara;
Steinhauer, Sonja; Hantel, Constanze; Rost, Simone; Rosenwald, Andreas; Kroiss, Matthias;
Fassnacht, Martin; Sbiera, Silviu; Ronchi, Cristina
DOI:
10.3389/fendo.2020.00219
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Liang, R, Weigand, I, Lippert, J, Kircher, S, Altieri, B, Steinhauer, S, Hantel, C, Rost, S, Rosenwald, A, Kroiss,
M, Fassnacht, M, Sbiera, S & Ronchi, C 2020, 'Targeted gene expression profile reveals CDK4 as therapeutic
target for selected patients with adrenocortical carcinoma', Frontiers in Endocrinology, vol. 11, 219.
https://doi.org/10.3389/fendo.2020.00219
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
ORIGINAL RESEARCH
published: 16 April 2020
doi: 10.3389/fendo.2020.00219
Frontiers in Endocrinology | www.frontiersin.org 1 April 2020 | Volume 11 | Article 219
Edited by:
Antonio Brunetti,
University of Catanzaro, Italy
Reviewed by:
Holger S. Willenberg,
University Hospital Rostock, Germany
Christopher Gerner,
University of Vienna, Austria
*Correspondence:
Cristina L. Ronchi
ronchi_c@ukw.de;
c.l.ronchi@bham.ac.uk
Specialty section:
This article was submitted to
Systems Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 28 November 2019
Accepted: 26 March 2020
Published: 16 April 2020
Citation:
Liang R, Weigand I, Lippert J,
Kircher S, Altieri B, Steinhauer S,
Hantel C, Rost S, Rosenwald A,
Kroiss M, Fassnacht M, Sbiera S and
Ronchi CL (2020) Targeted Gene
Expression Profile Reveals CDK4 as
Therapeutic Target for Selected
Patients With Adrenocortical
Carcinoma. Front. Endocrinol. 11:219.
doi: 10.3389/fendo.2020.00219
Targeted Gene Expression Profile
Reveals CDK4 as Therapeutic Target
for Selected Patients With
Adrenocortical Carcinoma
Raimunde Liang 1, Isabel Weigand 1, Juliane Lippert 1,2, Stefan Kircher 3, Barbara Altieri 1,4,
Sonja Steinhauer 1, Constanze Hantel 5,6, Simone Rost 2, Andreas Rosenwald 3,7,
Matthias Kroiss 1, Martin Fassnacht 1,7, Silviu Sbiera 1 and Cristina L. Ronchi 1,8*
1Division of Endocrinology and Diabetology, Department of Internal Medicine, University Hospital of Wuerzburg, Würzburg,
Germany, 2 Institute of Human Genetics, University of Wuerzburg, Würzburg, Germany, 3 Institute of Pathology, University of
Wuerzburg, Würzburg, Germany, 4Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University
of Naples Federico II, Naples, Italy, 5Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital
Zurich, Zurich, Switzerland, 6Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden,
Germany, 7Comprehensive Cancer Center Mainfranken, University Hospital of Wuerzburg, Würzburg, Germany, 8 Institute of
Metabolism and System Research (IMSR), University of Birmingham, Birmingham, United Kingdom
Adrenocortical carcinomas (ACC) are aggressive tumors with a heterogeneous prognosis
and limited therapeutic options for advanced stages. This study aims to identify
novel drug targets for a personalized treatment in ACC. RNA was isolated from 40
formalin-fixed paraffin-embedded ACC samples. We evaluated gene expression of 84
known cancer drug targets by reverse transcriptase quantitative real time-PCR and
calculated fold change using 5 normal adrenal glands as reference (overexpression by
fold change>2.0). Themost promising candidate cyclin-dependent kinase 4 (CDK4) was
investigated at protein level in 104 ACC samples and tested by in vitro experiments in
two ACC cell lines (NCI-H295R and MUC1). The most frequently overexpressed genes
were TOP2A (100% of cases, median fold change = 16.5), IGF2 (95%, fold change
= 52.9), CDK1 (80%, fold change = 6.7), CDK4 (62%, fold change = 2.6), PLK4 (60%,
fold change= 2.8), and PLK1 (52%, fold change= 2.3). CDK4 was chosen for functional
validation, as it is actionable by approved CDK4/6-inhibitors (e.g., palbociclib). Nuclear
immunostaining of CDK4 significantly correlated with mRNA expression (R = 0.52,
P < 0.005). We exposed both NCI-H295R and MUC1 cell lines to palbociclib and
found a concentration- and time-dependent reduction of cell viability, which was more
pronounced in the NCI-H295R cells in line with higher CDK4 expression. Furthermore, we
tested palbociclib in combination with insulin-like growth factor 1/insulin receptor inhibitor
linsitinib showing an additive effect. In conclusion, we demonstrate that RNA profiling
is useful to discover potential drug targets and that CDK4/6 inhibitors are promising
candidates for treatment of selected patients with ACC.
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INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare and aggressive
tumor with generally poor but heterogeneous prognosis, which
can be assessed by initial tumor stage and histopathological
parameters like Ki67 proliferation index (1, 2). The presence of
metastatic disease is associated with overall 5 year survival of
<15% (1, 3, 4).
Current treatment options for ACC patients are scarce,
with the only potential curative therapy being complete
surgical resection (R0) (5). The adrenolytic drug mitotane is
the only approved drug for treatment of ACC and can be
administered as adjuvant therapy (6) or to patients with advanced
disease (7). Cytotoxic chemotherapies such as etoposide-
doxorubicin-cisplatin (EDP), streptozotocin and gemcitabine
plus capecitabine represent further options but all show low
response rates and frequent adverse effects (8–10). In addition,
despite the proposal of some predictive markers of treatment
response (9, 11), none of these have been applied clinically to
predict responses in an individual patient.
Precision medicine represents an emerging approach in
the field of cancer treatment. It involves molecular analyses
to identify potentially targetable genes or pathways and then
pre-select the most effective personalized therapy options. For
ACC, biomarkers such as specific transcriptomic profiles, copy
number alteration patterns and methylation in certain promoter
regions have been identified by genome-wide studies to be
associated with tumor aggressiveness and clinical outcome (12–
15). In addition, previous molecular screenings have provided
some promising insights into pharmacological targets, such as
proteins involved in the cell cycle or tyrosine kinase receptors
(2, 16, 17). The efficacy of some of these potential targets
have previously been investigated in small clinical studies,
but patients were not pre-selected and results were largely
negative (18–23). Linsitinib, a dual inhibitor of the insulin-
like growth factor 1 (IGF1R) and of the insulin receptor
(IR), represents the only drug to have entered a phase III
trial for ACC patients, but it also yielded disappointing
results (24). However, it must be acknowledged that the
molecular background of included patients in this trial was
largely unknown.
Although our understanding of complex and heterogeneous
ACC pathogenesis has improved through pan-genomic
molecular studies over the last decade a targeted therapy is
not yet available for patients with advanced disease. This
concept has been recently well-summarized in a comprehensive
review on genomic-guided clinical care in ACC (25). In a
recent study, we demonstrated that a molecular screening
performed by targeted next-generation sequencing on 107
available formalin-fixed paraffin-embedded (FFPE) tumor
specimens was able to identify simultaneously prognostic
markers and potential drug targets (2). The aim of the
present study was to identify actionable genes and pathways
at the mRNA level that might serve as a future personalized
therapy in ACC. To this end, we performed targeted gene
expression profiling on ACC tumor samples and functional in
vitro studies.
MATERIALS AND METHODS
Patient Cohort and Clinical Data
A total of 107 patients with histologically confirmed diagnosis
of ACC and available DNA sequencing data from a previous
publication were considered for this study (2). From these,
104 cases were included with available FFPE tumor specimens
collected between 2002 and 2016. A total of 40 out of these
104 cases (33 primary tumors, 5 local recurrences, and 2
distant metastases) were also used for mRNA analysis (mRNA
cohort, see below). Baseline clinical and histopathological
characteristics, follow up information and details about
pharmacological treatment (i.e., mitotane and/or cytotoxic
chemotherapies) were collected through the ENSAT registry
(https://registry.ensat.org//) and are summarized in Table 1.
Furthermore, 9 normal adrenal glands (NAG) specimens and 11
adrenocortical adenoma (ACA) specimens were used as controls
for immunohistochemistry analysis and 5 NAG as reference for
gene expression analysis. The study protocol was approved by
the local ethics committee (University Hospital of Wuerzburg,
#88/11) and written informed consent was obtained from all
subjects prior to study enrollment.
RNA Isolation, Quality Testing, and
Targeted mRNA Profiling
The tumor cell content of each FFPE slide was assessed by
hematoxylin-eosin staining (median 90%, range 60–95%). RNA
was isolated from tumors using miRNeasy FFPE kit (Qiagen,
Hilden, Germany) according to manufacturer’s instructions.
One microgram of isolated RNA was reverse transcribed using
the Quantitec Reverse Transcription Kit (Qiagen). RNA quality
was determined by quantitative real-time PCR (RT-qPCR)
for two housekeeping genes, ACTB (Hs9999903_m1) and
GAPDH (Hs99999905_m1) (Applied Biosystems, Darmstadt,
Germany), using the TaqMan Gene Expression Master Mix
(Applied Biosystems), the CFX96 real-time thermocycler
(Biorad, Hercules, CA, USA) and the Bio-Rad CFX Manager 2.0
software. Forty nanogram cDNA was used per reaction and run
in duplicates. Cycling conditions were 95◦C for 3min, followed
by 49 cycles of 95◦C for 30 s, 60◦C for 30 s, and 72◦C for 30 s.
A cycle threshold (CT) of ≤39 was required as quality test for
targeted mRNA analysis. Accordingly, 40 samples qualified
for further analysis (mRNA cohort) and were transcribed with
the RT2 First Strand Kit (Qiagen) according to manufacturer’s
protocol. Expression of a panel of 84 drug targetable genes
as well as five housekeeping genes (ACTB, B2M, GAPDH,
HPRT1, RPLP0) and seven positive control genes was evaluated
by the Human Cancer Drug Targets RT2 Profiler PCR Array
(PAHS-507Z, Qiagen). The reaction was performed with the RT2
SYBRGreen qPCRMastermix (Qiagen). Cycling conditions were
95◦C for 10min followed by 40 cycles of 95◦C for 15 s, 60◦C for
1min. Fold change (FC) was calculated with the 2∧(−11CT)
formula normalized to five housekeeping genes and with a pool
of five NAG from FFPE specimens as reference by the Qiagen
GeneGlobe Data Analysis Center (https://www.qiagen.com/
de/shop/genes-and-pathways/data-analysis-center-overview-
page).
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TABLE 1 | Clinical and histopathological characteristics of patients with
adrenocortical carcinomas in the entire cohort and in subgroup used for mRNA
expression analysis (mRNA cohort).
Total cohort mRNA cohort
n 104 40
Sex (F/M) 59/45 25/15
Baseline
Age—yrs (median, range)
<50 years—n (%)
≥50 years—n (%)
49 (18–87)
54 (51.9)
50 (48.1)
46 (18–81)
24 (60.0)
16 (40.0)
Steroid secretion—n available
Cortisol—n (%)
Other single steroids (androgens,
mineralocorticoids, or estrogens)—n (%)
Mixed steroids—n (%)
Inactive—n (%)
78
23 (22.1)
9 (8.7)
21 (20.2)
25 (24.0)
33
9 (22.5)
4 (10.0)
9 (22.5)
11 (27.5)
Tumor localization
Primary tumor—n (%)
Local recurrences—n (%)
Metastases—n (%)
87 (83.7)
8 (7.7)
9 (8.6)
33 (82.5)
5 (12.5)
2 (5.0)
ENSAT tumor stage
I-II—n (%)
III—n (%)
IV—n (%)
55 (52.9)
27 (26.0)
22 (21.1)
21 (52.5)
14 (35.0)
5 (12.5)
Resection status—n available
R0—n (%)
RX—n (%)
R1—n (%)
R2—n (%)
101
72 (69.2)
16 (15.4)
5 (4.8)
8 (7.7)
40
28 (70.0)
7 (17.5)
3 (7.5)
2 (5.0)
Ki67 proliferation index—median (range) 15 (2–90) 17.5 (3–90)
Follow-up
Duration of follow up—months
(median, range)
Deaths
36 (1–280)
53 (51.0)
31 (4–280)
18 (45.0)
Therapeutic approaches
Additional surgeries—n (%)
Radiotherapy (tumor bed or
metastases)—n (%)
38 (36.5)
32 (30.8)
18 (45.0)
15 (37.5)
Mitotane
Adjuvant setting—n (%)
Palliative setting—n (%)
38 (36.5)
38 (36.5)
16 (40.0)
14 (35.0)
Cytotoxic chemotherapies
None—n (%)
Platinum-based regimen—n (%)
Streptozotocin—n (%)
Gemcitabin plus capecitabin—n (%)
Iodmetomidate—n (%)
41 (39.4)
53 (51.0)
43 (41.3)
37 (35.6)
4 (3.8)
17 (42.5)
18 (45.0)
19 (47.5)
14 (35.0)
4 (10.0)
F, female; M, male; n, number of patients; R0, complete resection; R1, microscopic
incomplete resection; R2, macroscopic incomplete resection; RX, uncertain resection;
yrs, years.
Selection of Drug Target Candidate
We assessed the potential of the most frequently overexpressed
genes as drug targetable events. First selection criterion was based
on high frequency of gene overexpression in our ACC series (i.e.,
FC ≥2.0 in at least 50% of cases). According to this, we pre-
selected a total of 6 candidates. The current stage of inhibitors
targeting this gene candidates is listed in Table 2. Second
selection criterion was the availability of specific inhibitors
TABLE 2 | Currently available inhibitors targeting the most frequently
overexpressed genes reported in the present study.
Gene Available inhibitors
(examples)
Current stage
IGF2 IGFR/IR inhibitor (e.g.,
linsitinib)
Phase III trial in ACC patients
(OSI-906)a
TOP2A TOP2A inhibitors (e.g.,
aclarubicin)
Preclinical studies in ACC cellsb
CDK1 Pan-CDK inhibitors
(e.g., flavopiridol)
Phase I/II trials ongoing in solid
tumors
Preclinical studies in ACC cellsc
CDK4 CDK4/6 inhibitors
(e.g., palbociclib)
FDA and EMA approved for
EGFR-negative breast cancer
Phase II trials in liposarcoma
Preclinical studies in ACC cellsd
PLK4 PLK4 inhibitor
(fumarate)
Phase I trials ongoing in solid tumors
PLK1 PLK1 inhibitor (e.g.,
TKM-080301)
Phase I/II trials ongoing in solid
tumors
aFassnacht et al. (24); bJain et al., (26); cNilubol et al., (27); dFiorentini et al. (28).
FDA, Food and Drug Association; EMA, European Medical Association.
Sources: www.clinicaltrials.com, www.ema.europa.eu/en/medicines, www.fda.gov/
drugs/informationondrugs/approveddrugs.
already approved by both U.S. Food and Drug Association
(FDA) and/or European Medical Association (EMA) or at least
in phase III clinical trials on solid tumors. Consequently, we
choose cyclin-dependent kinase 4 (CDK4) as only ideal candidate
for further investigation. We also checked for CDK4 expression
levels in previously published data sets fromAffimetrix U133 Plus
2 chips that included 33 ACC as well as 22 adenomas and 10 NAG
(GSE10297) (29) for further confirmation of our observation.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 2µm thick
sections of 104 ACC specimens, while 11 ACA and 6 NAG
were additionally stained as controls. After deparaffinization,
antigen retrieval was achieved by heating the slides for 13min
in the pressure cooker in 10mM citric acid monohydrate
buffer (pH 6.5). Unspecific binding sites were blocked with
20% human AB serum at room temperature (RT) for 1 h
and slides were then incubated at RT for 1 h with specific
antibodies against CDK4 (EPR4513-32-7, Abcam, Cambridge,
United Kingdom, dilution 1:20) or N-Universal Negative control
anti-rabbit (Dako, Golstrup, Denmark). Antibody binding was
detected by means of the En-Vision System Labeled Polymer-
HRP and developed for 10min with DAB Substrate Kit (Vector
Laboratories, Burlingame, CA, USA). Nuclei were counterstained
with Mayer’s hematoxylin. Other tissues, such as normal tonsil
and thyroid carcinoma were included as positive controls.
Evaluation of stained slides was performed by two
independent operators blinded to the results and clinical
information (R.L. and S.St.). Intensity of nuclear staining and
percentage of positive cells were rated as previously described,
in order to calculate a semi-quantitative H-score (11). In case of
discrepancies, slides were jointly assessed by both investigators
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and a final score was developed by consensus. Inter-observer
agreement was determined by Pearson’s correlation coefficient:
0.67 (95% CI = 0.55–0.76). The median CDK4 H-score was
used for stratification of the patient cohort by CDK4 protein
expression (n = 72 with CDK4 H-score ≤1 and n = 32 with
CDK H-score>1).
Adrenocortical Carcinoma Cell Lines and
in vitro Experiments
CDK4 was selected to be investigated by in vitro experiments.
Two ACC cell lines were used to test the efficacy of selected
inhibitors targeting CDK4: the standard ACC cell line NCI-
H295R and the newly established MUC1 cell line (30). Details
about cell culture conditions as well as functional experiments
are reported in Supplementary Table 1. In brief, to investigate
genetic alterations and expression patterns of CDK4 and
its related genes, targeted next-generation sequencing was
performed as previously published (2) and the Human Cancer
Drug Targets RT2 Profiler PCR Array was obtained for both
cell lines.
For CDK4 small interfering RNA (siRNA)-knock down,
NCI-H295R or MUC1 cells were incubated with SMARTpool
siRNA for CDK4. Moreover, cells were incubated with increasing
drug concentrations of palbociclib (known CDK4/6 inhibitor,
0.5–16µM) (31). Seventy two hours post-transfection with
siRNA or upon completion of the drug treatment, cells were
collected for RT-qPCR analysis or western blot (WB) analysis
to demonstrate knock-down of CDK4 or examine changes in
RNA and protein expression in the CDK4/6 pathway. The
Hek293 and Hela cells were used as positive controls for
CDK4 and cyclin-dependent kinase inhibitor 2A (CDKN2A)
mRNA expression, as previously published (32). Cell viability
was assessed by the water-soluble tetrazolium (WST-1) reagent
according to manufacturer’s instructions (Roche Diagnostics
Deutschland GmbH, Mannheim, Germany). In addition, cells
were treated with increasing concentrations of dual IGF1R/IR
inhibitor linsitinib (OSI-906, Selleckchem, 0.125–4µM), which
effectively reduces cell viability in NCI-H295R cells (33, 34). It is
recognized IGF signalingmay lead to activation of cyclin D by the
phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT)
pathway (Figure 3C). Inhibition of CDK4/6 and IGF1R achieved
synergistic compromise of cell viability and proliferation while
showing a correlation with reduced mammalian target of
rapamycin complex 1 (mTORC1) activity (35, 36). For this
reason, we decided to test the efficacy of CDK4/6 inhibitors
in combination with linsitinib incubating both cell lines with a
combination of palbociclib and linsitinib for 48, 96, 144, and
192 h. At least eight wells were used for each experimental
condition and all experiments were conducted in triplicates.
Western Blot (WB) Analysis
Details about WB analysis conditions are reported in
Supplementary Table 1. In brief, after cell lysis, equal amount
of proteins was loaded on a 4–20% gradient gel (BioRad) and
separated by SDS-PAGE. The membrane was further probed
with antibodies against CDK4 (EPR4513-32-7, abcam, dilution
1:1000) and CDKN2A (G175-405, BD Pharmingen, San Jose,
CA, USA, dilution 1:500).
It is also known that CDK4, along with CDK6, activated by
binding to D-type cyclins, is responsible for the G1-S phase
transition in the cell cycle by phosphorylating and inhibiting the
retinoblastoma (RB) protein and the related proteins p107/RBL1
and p130/RBL2 (36). Moreover, CDK4/6 inhibitors have been
reported to reduce cell viability in ACC cell lines despite lack
of pRb expression (28, 31) p130/RBL2 being already reported
to be expressed in the NCI-H295R cell line (28). Thus, we
investigated RB and p130/RBL2 protein expression in both
cell lines. Signal detection was achieved by incubation with
appropriate HRP-labeled secondary antibodies and Amersham
ECL Prime reagent visualizing the protein-antibody complex by
enhanced chemiluminescence.
Statistical Analysis
A Fisher’s exact or Chi-square test was used to investigate
dichotomic variables, while a two-sided t-test or non-parametric
Mann-Whitney test was used to compare two groups of
continuous variables as appropriate. A non-parametric Kruskal-
Wallis test followed by Bonferroni post-hoc test, was used for
comparison among several groups for non-normal distributed
variables. Correlations and 95% confidence intervals (95% CI)
between different parameters were evaluated by linear regression
analysis. Overall survival (OS) was defined as the time from the
date of primary surgery to specific death or last follow-up, while
progression-free survival (PFS) was defined as the time from the
date of complete tumor resection to the first radiological evidence
of disease relapse or disease-related death. Time to progression
(TTP) during therapy was defined as the time from the date of
first drug administration to the first radiological evidence of any
kind of disease progression or relapse or death. Survival curves
were obtained by Kaplan-Meier estimates and the differences
between two or more curves were investigated by the log-rank
(Mantel-Cox) test. A multivariate regression analysis including
parameters with p-values below 0.1 at univariate analysis was
performed by Cox proportional hazard regression model to
identify the factors that might independently influence survival.
Statistical analysis was performed with GraphPad Prism software
6.0 (GraphPad Software Inc., La Jolla, CA, USA) or SPSS software
(IBM SPSS statistics, version 24). P-values below 0.05 were
considered statistically significant.
RESULTS
Overview of Gene Expression Profile
(mRNA Cohort)
Among the 84 investigated genes, 16 were relatively
overexpressed with a FC ≥ 2.0 in at least 25% of samples,
while 54 genes presented a FC < 2 in at least 25% of samples.
The percentage of samples with overexpression for each gene is
shown in Figure 1. The six most frequently overexpressed genes
were topoisomerase 2-alpha (TOP2A, 100% of cases, median FC
16.5, range: 2.0 to 126.7), insulin-like growth factor 2 (IGF2, 95%
of cases, median FC 52.9, range: −58.6 to 532.9), CDK1 (80% of
cases, median FC 6.7, range: −1.3 to 27.4), CDK4 (62% of cases,
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FIGURE 1 | Gene overexpression in a cohort of 40 adrenocortical carcinoma samples. Percentage of samples with relative overexpression for 84 known cancer drug
target genes (RT-qPCR profile, for details see Material and Methods). A fold change of ≥2.0 was defined as high expression whereas a fold change ≥5.0 was defined
as very high expression.
median FC 2.6, range: −1.5 to 15.0), polo like kinase (PLK) 4
(60% of cases, median FC 2.8, range: −1.6 to 36.0), and PLK1
(52% of cases, median FC 2.3, range:−2.7 to 33.9).
Additionally, some gene families were found to be upregulated
in more than 50% of samples: Aurora Kinase (AURK, 62.5%
of cases with at least one member overexpressed), CDK (95%
of cases) and PLK (75% of cases, Figure 1). Notably, while
IGF2 was observed to be strongly overexpressed, both IGF1
and IGF1R were downregulated in most cases (median FC
−2.9, range: −67.8 to 3.0, and median FC −1.7, range:
−25.5 to 3.0, respectively). CDK4 expression levels were not
associated with IGF2, IGF1 nor IGF1R levels, but 37.5% of cases
presented high CDK4 and normal/high IGF1R expression levels
(Supplementary Figures 1A,B).
Furthermore, we observed a significant positive correlation
between Ki67 proliferation index and mRNA expression of
AURKB, cell division cycle 25A (CDC25A), CDK1, CDK2, fms-
related tyrosine kinase 1 (FLT1), histone deacetylase 2 (HDAC2),
MTOR, poly (ADP-ribose) polymerase 1 (PARP1), platelet
derived growth factor receptor beta (PDGFRB) and TOP2A (data
not shown).
CDK4 as Promising Drug Target for ACC
According to our selection criteria, CDK4 was chosen as the
most promising targetable drug candidate. Alterations in cell
cycle regulation are frequently observed in ACC development
and considered to be important ACC drivers. In particular, cell
cycle alterations related to the p53/Rb1 pathway constitute an
attractive target for cancer therapy (37). Of note, CDK4 copy
number (CN) gains, as well as losses of its regulator, CDKN2A,
are frequently reported in ACC (14–16). In our entire ACC
cohort (n= 104), previously analyzed by targeted next generation
sequencing, CN gains for CDK4 were observed in 43% of cases
(2). Comparing CDK4 CN status and mRNA expression, ACC
with normal CN status (n = 24) showed significantly lower
mRNA expression than ACC with CDK4 CN gains (n= 16) (p=
0.0085 by Kruskal-Wallis test, Figure 2A). In addition, looking
at available transcriptome data sets (29), a significantly higher
CDK4 expression can be likewise observed in ACC vs. both
adenomas and NAG (Supplementary Figure 2).
CDK4 Protein Expression: Relationship
With Gene Expression and Clinical
Outcome
CDK4 expression was evaluated by immunostaining in our entire
ACC series (n = 104). Two representative examples for CDK4
immunostaining in ACC samples are shown in Figures 2B,C,
while the cohort stratification by low and high CDK4
nuclear H-score is reported in the Supplementary Table 2.
Considering separately the mRNA cohort (n = 40), a significant
positive correlation between CDK4 mRNA and nuclear protein
expression was observed (p = 0.0005, R = 0.52, Figure 2D).
However, only a positive trend was detected between CN status
and CDK4 protein expression in the entire cohort (n = 104, p
= 0.2285, data not shown). Overall, we observed a significantly
higher nuclear CDK4 expression (H-score) in ACC (n = 104)
than in both ACA (n = 11, p < 0.01) and NAG (n = 6, p <
0.01), while no difference was observed between ACA and NAG
(Figure 2E).
Considering the clinical outcome (n = 104 ACC), OS showed
no relationship with CDK4 protein expression (p = 0.2013,
data not shown), while PFS was slightly longer in patients with
high CDK4 nuclear expression compared to patients with low
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FIGURE 2 | CDK4 gene expression and CDK4 nuclear protein expression in adrenocortical carcinoma (ACC). (A) Relationship between CDK4 gene expression and
copy number (CN) status at DNA level (n = 40) (2): CDK4 mRNA fold changes (FC) in ACC with normal CN status (n = 23) or CDK4 CN gain heterozygous (n = 13) or
(Continued)
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FIGURE 2 | homozygous (n = 4) as previously published. Bars represent median and interquartile range. *p < 0.05. Statistical analysis by Kruskal-Wallis test followed
by Bonferroni post-hoc test. (B,C) Examples of CDK4 immunostaining in two ACC samples, one with negative nuclear staining (H-score = 0) and one with
intermediate positive staining (H-score = 2). Magnification 1 × 20. (D) Relationship between CDK4 mRNA FC and CDK4 nuclear protein expression evaluated by
immunohistochemistry (as H-score) (n = 40). The regression line is shown. Statistical analysis by Pearson r correlation test. (E) CDK4 nuclear protein expression
evaluated by immunohistochemistry (as H-score) in normal adrenal glands (NAG, n = 6), adrenocortical adenomas (ACA, n = 11) and ACC samples (n = 104) (p <
0.0002 per trend). Bars represent median and interquartile range. **p < 0.01. Statistical analysis by Kruskal-Wallis test. (F) Progression-free survival curves comparing
low CDK4 expression defined as H-score ≤ 1 (n = 72) and high expression defined as H-score > 1 (n = 32). Statistical analysis by log-rank test. (G) Time to
progression in platinum-treated ACC cohort (n = 53) comparing low expression (n = 38) and high expression (n = 15) as defined above. Statistical analysis by
log-rank test.
expression (median=24 vs. 9 months, p = 0.0122, HR = 0.56,
95% CI = 0.36–0.88, Figure 2F). As expected, PFS was also
significantly associated with ENSAT tumor stage (stage 1–2 vs. 3–
4, p= 0.001, HR= 2.25, 95% CI= 1.39–3.64), Ki67 proliferation
index (cut-off 15%, p < 0.001, HR = 3.53, 95% CI = 2.11–
5.89), and resection status (R0-X vs. R1–2, p < 0.001, HR =
6.49, 95% CI 2.5–16.8). Of note, including these parameters in a
multivariate analysis, the relationship between CDK4 expression
and PFS remained statistically significant (p= 0.044, HR= 0.45,
95% CI = 0.20–0.98). Further investigation showed that high
CDK4 protein expression was significantly associated with longer
TTP during treatment with platinum-based chemotherapy (n =
53, median 6 vs. 4 months, p= 0.0156, HR= 3.1, 95% CI= 1.4–
6.7) (Figure 2G). No other significant relationship was observed
between CDK4 immunostaining and response to therapy.
Expression of CDK4-Related Genes and
Proteins in ACC Cell Lines
No CN variations in the genes CDK4 and CDKN2A were
observed in either NCI-H295R or MUC1 cells. RB gene losses
were found in NCI-H295R cells, but not in MUC1 cells. A
specific mRNA profile of CDK4-related genes was obtained
and validated on protein level (Figures 3A,B). In particular,
CDK4 mRNA expression was relatively high in NCI-H295R
(2.50 ± 1.01) and moderate in MUC1 cells (0.81 ± 0.25),
these findings being reinforced by WB analysis in comparison
to other CDK4 expressing cell lines as positive controls
(Supplementary Figure 3). A rather high CDKN2A mRNA
expression was detected in both NCI-H295R (2.30± 1.19) and in
MUC1 (2.89± 0.53) cell lines, while CDKN2A/p16INK4A protein
expression was clearly lower in NCI-H295R cells than MUC1
cells. No mRNA expression of RB1 was observed in NCI-H295R
and expression was low in MUC1 cells (0.09 ± 0.06), while no
RB1 protein expression was shown in both cell lines. On the
other side, p130/RBL2 was consistently expressed in both ACC
cell lines. CDK1, CDK6, and CCND1 mRNA were expressed at
low levels in both ACC cell lines (all<0.4).
Additionally, RT profiling showed a very strong IGF2
overexpression (FC > 2,000) and a strong IGF1R overexpression
(FC= 4.1) in NCI-H295R cells associated with a downregulation
of IGF1 (FC= −32). MUC1 cells presented IGF2 (FC>20.0) and
IGF1R (FC= 2.8) overexpression and regular expression of IGF1
(FC= 1.2) (Figure 3C).
CDK4 Inhibition by siRNA in ACC Cell Lines
NCI-H295R cells and MUC1 cells were successfully transfected
withCDK4 siRNA. 72 h after transfection,CDK4was significantly
reduced in comparison to mock transfected control cells in
both cell lines at mRNA (60% reduction, p = 0.0175, and
85% reduction, p = 0.0022, for NCI-H295R cells and MUC1
cells, respectively, Supplementary Figure 4A) and protein level
(80% reduction, p = 0.0039, and 95% reduction, p =
0.0004, for NCI-H295R cells and MUC1 cells, respectively,
Supplementary Figure 4B). WST1 assays were performed to
examine the impact of CDK4 downregulation on cell viability.
Whereas, CDK4 knockdown in NCI-H295R showed a significant
decrease of cell viability when compared to the control (88.6 ±
9.3 vs. 100.0 ± 8.6, p < 0.0001) (Supplementary Figure 4C), no
clear effect was detected in MUC1 cells (97.0 ± 7.6 vs. 100.0 ±
6.9, p= 0.175) (Supplementary Figure 4C).
Treatment With CDK4/6 Inhibitor
Palbociclib in ACC Cell Lines
To assess the efficacy of palbociclib in vitro, the drug was
administered in increasing concentrations to NCI-H295R and
MUC1 cell lines. A time and dose dependent reduction of
cell viability was observed. Specifically, in NCI-H295R cells,
treatment with 2µM palbociclib reduced cell viability after
longer time intervals (96 and 192 h), while administration of
higher concentrations (i.e., 16µM) was already able to achieve
a decrease in cell viability at 48 h compared to vehicle treated
cells (82.3 ± 5.2 vs. 50.5 ± 19.2 vs. 48.9 ± 4.3 vs. 19.1 ± 4.6
at 48, 96, 144, 196 h, respectively, all p < 0.001) (Figure 4A).
Similar results were obtained in MUC1 cells, where a reduction
of cell viability was observed with both 8 and 16µM palbociclib
at all time points (81.7 ± 3.0 vs. 74.1 ± 8.7 vs. 63.8 ± 17.7
vs. 53.1 ± 10.9 for 16µM palbociclib at 48, 96, 144, 196 h,
respectively, all p< 0.001) (Figure 4A). However, comparing the
general effect of palbociclib in the two ACC cell lines, a stronger
decrease in cell viability was observed in NCI-H295R which was
obvious at higher drug concentrations or longer treatment times
(Supplementary Figure 5A).
Combined Treatment With Palbociclib and
Linsitinib in ACC Cell Lines
Linsitinib alone significantly reduced cell viability in a
dose- and time-dependent manner in both cell lines
(Supplementary Figure 5B). To investigate a potential
combination of both palbociclib and linsitinib, 0.25µM
linsitinib and 4µM of palbociclib were administered to both
NCI-H295R and MUC1 cells and cell viability was measured at
48 and 96 h. Viability in NCI-H295R cells was significantly lower
in cells treated for 48 h with a combination of both drugs than in
single drug treatment (40.5 ± 9.7 vs. 54.7 ± 6.5 and 66.3 ± 15.6
for combination vs. linsitinib and palbociclib, respectively, both
p < 0.001) (Figure 4B). At 96 h a significant reduction of cell
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FIGURE 3 | Gene expression of CDK4-related factors in different adrenocortical carcinoma (ACC) cell lines. (A) mRNA expression levels of CDK1, CDK4, CDK6,
CCND1, CDK2NA, and RB1 in ACC cell lines NCI-H295R and MUC1 cells (triplicates by RT-qPCR). Hek293 and Hela cells were used as positive controls and β-actin
was used as housekeeping gene as internal standard. (B) Schematic representation of the cyclin-dependent kinases/cyclin complexes, their regulation by mitogenic
signals and their role in regulating the cell cycle progression as well as corresponding available inhibitors. Activating factors are represented in red, suppressor factors
in blue. (C) mRNA expression levels of IGF1, IGF1R, and IGF2 in ACC cell lines NCI-H295R and MUC1 cells (triplicates by RT-qPCR). β-actin was used as
housekeeping gene as internal standard.
viability remained only in comparison to palbociclib treatment
(51.4 ± 5.8 vs. 50.5 ± 4.2 and 66.0 ± 12.1 for combination vs.
linsitinib and palbociclib treatment, respectively, ns and p <
0.001). In MUC1 cells, treatment with the combination showed
a significant reduction in cell viability in comparison to linsitinib
(74.9 ± 3.6 vs. 78.5 ± 3.1, p < 0.05) and palbociclib (97.7 ±
4.8, p < 0.001) alone at 48 h. Significance of the effect of the
combination in respect to linsitinib alone increased (59.8 ±
3.8 vs. 68.0 ± 3.8, p < 0.001) at 96 h while comparison with
palbociclib remained unchanged (84.3± 2.3, p< 0.001).
Effects of Palbociclib and Linsitinib on
CDK4 Pathway
To better understand the effect of the drugs on the
CDK4 pathway, we investigated protein levels of CDK4,
CDKN2A/p16INK4A, and p130/RBL2 in cells after treatment
with palbociclib and linsitinib alone or in combination
(Figures 4C,D). No difference was shown in terms of CDK4 and
CDKN2A/p16INK4A. Contrarily, p130/RBL2 was significantly
decreased after palbociclib and combined treatment in both cell
lines NCI-H295R and MUC1, respectively (Figure 4D).
DISCUSSION
Despite intensive efforts and promising preliminary findings,
no effective targeted treatment is available for patients with
advanced ACC. In this study, we aimed to identify new potential
targeted therapies that might be used in the clinical setting in the
near future. To this end, we performed targeted gene expression
profiling on 40 standard FFPE tumor specimens focusing
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FIGURE 4 | Effects of treatment with CDK4/6 inhibitor palbociclib alone and in combination with linsitinib in adrenocortical cell lines: NCI-H295R (left) and MUC1
(right). (A) Interpolation of cell viability measured by WST1 test in 48 h intervals after administration of ascending concentrations of palbociclib. The mean of the
(Continued)
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FIGURE 4 | absorbance measured for cells treated with DMSO was defined as 100% for each experiment. The ratio of measured absorbance to the mean
absorbance forms the final data. For both cell lines three independent experiments were conducted using octuplet samples. *p < 0.05, ***p < 0.001 for comparison
with the control sample. Statistical analysis by two-way ANOVA. (B) Cell viability under additional administration of 0.25µM linsitinib and 4µM palbociclib in
NCI-H295R and MUC1 cells after 48 and 96 h. ns = p not significant, *p < 0.05, ***p < 0.001. Statistical analysis by one-way ANOVA. (C) Western blot analyses
show little effect after drug treatment for 96 h on protein expression of CDK4 and CDKN2A/p16INK4A but decreasing levels of p130/RBL2 after palbociclib treatment as
well as after treatment with the combination of palbociclib and linsitinib in both cell lines. The blot is representative for three independent experiments. ctrl-lin,
correspondent control to linsitinib treatment; lin, linsitinib; ctrl-pal, correspondent control to palbociclib treatment; pal, palbociclib treatment; ctrl-com, correspondent
control to combination treatment; com, combination of palbociclib and linsitinib. (D) Quantitative western blot analysis of p130/RBL2 in linsitinib, palbociclib and
combination treated cells. α-tubulin was used as the internal standard. Each corresponding control was defined as 1.0, each bar of the histograms represents the
relative ratio of p130/RBL2 to α-tubulin signal after normalization to the control. Each experiment was conducted in triplicates. ns = p not significant, *p < 0.05.
Statistical analysis by unpaired t-test with Welch’s correction.
on known anti-cancer drug targets. We identified promising
actionable gene families, such as CDK, PLK, and AURK families.
Considering the fact that (1) theCDK4 gene was overexpressed in
62% of ACC samples, (2) CDK4/6 inhibitors such as palbociclib
are already approved for breast cancers and under clinical trials
for other solid tumors, (3) CDK4 expression correlated with
the presence of CN gains at DNA level (2), and (4) palbociclib
has been previously tested in ACC cell lines with promising
results (28, 31), we decided to focus on CDK4 as our best
potential drug target for ACC. We also evaluated CDK4 protein
expression by immunohistochemistry in a large series of 104 ACC
samples and observed a strong correlation with mRNA levels.
In addition, CDK4 nuclear expression was associated to longer
PFS, even if not to longer OS. A similar association regarding
CDK4/6 specific activity was reported in high-risk endometrial
cancer (38). Additionally, we observed a correlation between
high CDK4 immunoreactivity and longer TTP during treatment
with platinum-based chemotherapy. CDK4 has previously been
reported to be one of the targets of cisplatin. High CDK4
expression could therefore be involved in better response to
therapy with platinum compounds (39) and thus explain at least
in part the longer PFS observed in the entire cohort. More
commonly, however, CDK4 is related to unfavorable prognosis
in several solid tumors (40). A larger cohort is definitely needed
for a sound statement on the prognostic role of CDK4 in ACC
patients. Altogether, even if high CDK4 levels might be associated
with favorable clinical outcome, we are convinced that there is
a strong rationale for using palbociclib in this group of ACC
patients. Indeed, about 50% of themwill have a recurrence within
the first 2 years after primary surgery and a good proportion of
them will need effective palliative pharmacological treatment.
We then performed functional in vitro studies in order
to test the effects of CDK4 inhibition on cell viability in
two different ACC cell lines (NCI-H295R and MUC1) (30).
CDK4/6 inhibitors (i.e., abemaciclib, palbociclib, and ribociclib)
were recently approved for hormone receptor positive, human
epidermal growth factor receptor 2 (EGFR)-negative, advanced
breast cancer in combination with hormone therapy (41, 42).
Currently, they are also under investigation in phase I and II
clinical trials on other solid tumors (43, 44) and in patients with
amplification or overexpression of CDK4 at tumor level (45)
(NCT03242382). Two recent studies on ACC cell lines already
showed the effect of CDK4/6 inhibitors on cell viability. While
Fiorentini et al. described the effect of palbociclib in dependence
with CDK4 and CDK6 mRNA overexpression in NCI-H295R
and SW13 cell lines (28), Hadjadj et al. investigated palbociclib
mainly under consideration of CDK6 expression (31). In our
study, we could confirm a concentration- and time-dependent
cell viability reduction through palbociclib in NCI-H295R cells
and for the first time also in the novel ACC cell line MUC1.
Of note, we observed that this effect was more evident in NCI-
H295R than in MUC1 cell line. This effect might be at least in
part due to the higher CDK4 expression observed in NCI-H295R
cells in contrast to MUC1 cells.
In terms of mechanisms, consistent with previous studies
reporting the deletion of the RB gene and lack of RB1 in a subset
of ACC tumors (14, 46), we found no RB1 protein expression
in neither NCI-H295R nor MUC1 cells, similarly to RB negative
palbociclib sensitive hepatoma cells. Therefore, we focused our
attention on p130/RBL2, a member of the RB-like family,
previously reported to be expressed in NCI-H295R cells (28, 31,
47). Indeed, we could show notable p130/RBL2 expression in
NCI-H295R as well as in MUC1 cells and also observed a relative
decrease of the p130/RBL2 protein in treated cells indicating
that CDK4 inhibition by palbociclib could actually lead to an
activation of p130/RBL2, which is involved in cell cycle arrest and
senescence (48).
However, present and previous studies on palbociclib in
ACC cell lines (31) utilized rather high drug concentrations
(i.e., 1–5µM) which would be difficult to maintain in patients,
implying that further investigations in animal models might
be needed to confirm the anticancer effects of palbociclib
for ACC.
IGF signaling is known to be activated in about 80–90% of
cases (49, 50) and the IGFR/IR inhibitor linsitinib has been
demonstrated to be a promising targeted therapy for ACC by
in vitro experiments (33). However, these encouraging findings
have not been confirmed in clinical trials, although a small
percentage of patients showed a partial response to treatment
(24). In the present series, we confirmed IGF2 overexpression in
95% of cases, whereas IGF1Rwas down-regulated in 45% of cases,
similarly as previously described (34). Of note, however, 37.5% of
cases presented high CDK4 and normal or high IGF1R mRNA
levels. On the other hand, an IGF1R overexpression is found
in NCI-H295R cells in our and previous studies (33, 34). Thus,
with IGF1R being the main target of linsitinib, its low/absent
expression in ACC might be one reason for the disappointing
response rate in ACC patients (24) and pre-screening for IGF1R
overexpression might then be useful to pre-select patients that
may benefit from this treatment. Another reason for linsitinib
failure might be represented by resistance mechanisms related
to CDK4/6 activation. In fact, it is recognized that IGF signaling
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activation can lead to upregulation of cyclin D1 and activation
of CDK4/6 (51). On this connection, we tested a combination
of palbociclib and linsitinib in ACC cell lines to examine the
effect of targeting two pathways simultaneously. Concurrent
inhibition of IGF1R and CDK4/6 has shown a greater decrease
in cell viability than achieved by a single drug in both NCI-
H295R and MUC1 cells, as reported in different tumor cell
lines (35, 52, 53). Currently, a phase Ib clinical trial with
an IGF1/IGF2 antibody and CDK4/6 inhibitor is ongoing in
different solid tumors (NCT03099174). To date, mitotane or the
combination ofmitotane with the cytotoxic regimen of etoposide,
doxorubicin and cisplatin (EDP-M) is recommended as first-line
treatment of advanced ACC (8). Mitotane is generally considered
as a toxic drug with a narrow therapeutic range, adverse
events often limiting the dosage mostly include gastrointestinal
disorders and neurological effects (5). EDP-M is currently the
most validated option for advanced ACC, however, response
rates remain low. Common adverse events are hematological,
gastrointestinal and neurological effects (5, 8). Both palbociclib
and linsitinib were reported to be mostly well-tolerated with
the most common adverse events being hematologic toxicity
under palbociclib (54) and fatigue, nausea and hyperglycemia
under linsitinib (24). Thus, even a combination of Palbociclib
and linsitinib remains theoretically competitive compared
to EDP-M.
In conclusion, our easy-to-apply screening approach allowed
us to identify promising target genes that might serve for
personalized management of patients with advanced ACC. In
particular, it seems to be feasible in the near future to pre-
select ACC patients that might potentially benefit from a
treatment with CDK4/6 inhibitors, consistent with the presence
of CDK4 CN gains (at DNA level, 43% of cases) and/or
CDK4 overexpression (at mRNA or protein level) in the tumor,
while linsitinib might be an interesting combination partner in
patients with both IGF2 and IGF1R overexpression. Our study
is the preclinical basis for a clinical trial investigating CDK4/6
inhibitors in ACC, a disease in which personalized therapeutic
approaches are urgently needed.
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